AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$TXG

What 10x Genomics (TXG) Said on Its Q3 Earnings Call

10x Genomics (TXG) reported Q3 earnings, with consumables revenue up 5% YoY, driven by spatial products. Instrument revenue fell 43%, attributed to fewer units sold. Gross margin rose to 75% but is expected to decline in Q4 due to Atera instrument shipments. The company ended the quarter with $576M in cash. TXG also announced new software and clinical initiatives.

Original reporting
finance.yahoo.com
Published Nov 6, 2026, 2:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 2:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What 10x Genomics (TXG) Said on Its Q3 Earnings Call — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TXGBullishMed
01

Why it matters

The earnings mix shift and margin outlook suggest short‑term pressure, but longer‑term growth from Atera and software may be undervalued.

02

Market read

First‑time disclosure of Q3 numbers and Q4 guidance for a mid‑cap biotech tool maker; relevant for investors in genomics and biotech instrumentation.

03

What to watch

Potential upside from the new Sentira cloud platform and upcoming CLIA lab could unlock software revenue streams not reflected in current guidance.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

10x Genomics reported Q3 results, highlighting a shift toward consumables revenue and a new cloud analysis platform, while providing guidance for Q4 consumables growth.

Company-level read

Ticker impact

$TXGBullishHigh confidence
Context

Q3 earnings call disclosed consumables revenue up 5% YoY, instrument revenue down 43%, gross margin rose to 75% and guidance for double‑digit consumables growth in Q4.

Expected impact

likely downside as investors price in lower instrument revenue and margin compression

Evidence & confidence

The mix shift to higher‑margin consumables is positive, but a 43% drop in instrument revenue and guidance of lower gross margins suggest near‑term earnings pressure.

Market effects

Sector

Signals continued demand for single‑cell consumables while instrument sales lag, affecting peers in the life‑sciences instrumentation space.

Regional

Primarily U.S. biotech and pharma research spend; limited broader market effect.

Global

Modest impact on global genomics tooling market as 10x's Atera rollout gains traction.

Counterpoint

What could challenge this read

If consumables growth accelerates faster than guidance, the stock could rally on margin improvement.

Key entities

  • Company
    10x Genomics

    Life‑sciences technology firm (NASDAQ:TXG).

  • Product
    Sentira

    New cloud analysis platform announced during the call.

Read at source← All news

Story10x Genomics reports Q3 2026 results and lifts full‑year revenue outlook

Also covered by

5 outlets

Related articles

$TXGMed

Stifel raises 10X Genomics stock price target on Atera outlook

Stifel raised 10X Genomics' (TXG) price target to $68 from $50, citing strong Q3 results and increased Atera placement expectations. The stock has risen 347% over the past year, trading at $58.06. Analysts predict profitability this year with an EPS of $0.10, though the stock appears overvalued. Revenue was $150.66M, beating estimates, but margins are expected to decline due to Atera shipments.

investing.com